Corcept Therapeutics | CORT - Assets


Corcept Therapeutics reported $823.61M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
ANI Pharmaceuticals USD 1.41B 65.15M Sep/2025
Ardelyx USD 486.17M 19.4M Sep/2025
Aurora Cannabis CAD 756.86M 80.98M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Canopy Growth CAD 1.07B 165.17M Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
J&J USD 192.82B 573M Sep/2025
Knight Therapeutics CAD 962.29M 16.93M Sep/2024
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pacira USD 1.3B 239.68M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Supernus Pharmaceuticals USD 1.42B 37.35M Sep/2025
TG Therapeutics USD 1.03B 322.41M Sep/2025